Ovarian cancer risk in postmenopausal women using estradiol–progestin therapy – a nationwide study

References

• Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and the risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007;13:453–63
   PubMed Web of Science ®Google Scholar
• Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009;115:531–9
   PubMed Web of Science ®Google Scholar
• Annegers JF, Strom H, Decker DG, Dockerty MB, O’Fallon WM. Ovarian cancer. Incidence and case-control study. Cancer 1979;43:723–9
   PubMed Web of Science ®Google Scholar
• Luoto R, Auvinen A, Pukkala E, Hakama M. Hysterectomy and subsequent risk of cancer. Int J Epidemiol 1997;26:476–83
   PubMed Web of Science ®Google Scholar
• Riman T, Dickman PW, Nilsson S, . Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497–504
   PubMed Web of Science ®Google Scholar
• Lacey JV, Brinton LA, Leitzmann MF, . Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP diet and health study cohort. J Natl Cancer Inst 2006;98:1397–405
   PubMed Web of Science ®Google Scholar
• Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 2548–56
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Green J, Reeves G, and Million Women Study collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703–10
   PubMed Web of Science ®Google Scholar
• Mørch LS, Løkkegaard L, Helms Andreasen A, Krüger-Kjær S, Lidegaard Ø. Hormone therapy and ovarian cancer. JAMA 2009;302:298–305
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl): 3–63
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354–60
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol–progestin therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Keskimäki I, Aro S, Teperi J. Regional variation in surgical procedure rates in Finland. Scand J Soc Med 1994;22:132–8
   PubMedGoogle Scholar
• Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365–9
   PubMed Web of Science ®Google Scholar
• Karlan BY, Markman MA, Eifel PJ. Gynecologic cancers, section 4. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2005:1364–67
   Google Scholar
• Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia: Lippincott-Raven Publishers, 1998:264.
   Google Scholar
• Auranen A, Hietanen S, Salmi T, Grénman S. Hormonal treatments and epithelial ovarian cancer risk. Int J Gynecol Cancer 2005;15:692–700
   PubMed Web of Science ®Google Scholar
• Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276:36869–72
   PubMed Web of Science ®Google Scholar
• Rahman KMW, Sarkar FH. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells. J Steroid Biochem Mol Biol 2002;80:191–201
   PubMed Web of Science ®Google Scholar
• Bu S, Yin D, Ren X, . Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944–50
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Walmer DK, Kline M, . Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest 1998;52:271–6
   Google Scholar
• Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis considering the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774–86
   PubMed Web of Science ®Google Scholar
• Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996;144:363–72
   PubMed Web of Science ®Google Scholar
• Purdie DM, Bain CJ, Siskind V, Hormone replacement therapy and the risk of epithelial ovarian cancer. Br J Cancer 1999;81:559–63
   PubMed Web of Science ®Google Scholar
• Soegaard M, Jensen A, Høgdall E, . Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007;16:1160–6
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer. A review of evidence. Drug Saf 1996;14: 260–72
   PubMed Web of Science ®Google Scholar
• Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999;32:141–5
   PubMed Web of Science ®Google Scholar
• Hammar M, Brynhildsen J, Dabrosin L, Hormone replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 1996;25:193–9
   PubMed Web of Science ®Google Scholar
• Sarantaus L, Vahteristo P, Bloom E, . BRCA1 and BRCA2 mutation among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001;9:424–30
   PubMed Web of Science ®Google Scholar
• Auranen A, Pukkala E, Mäkinen J, Sankila R, Grénman S, Salmi T. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer 1996;74:280–4
   PubMed Web of Science ®Google Scholar